Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Structure and Function of Platelets01:18

Structure and Function of Platelets

7.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.1K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In a nutshell: Pandora's Box-B-cell lymphoproliferation masking inborn errors of immunity.

British journal of haematology·2026
Same author

Thrombopoietin agents and marrow fibrosis: fact or myth.

Haematologica·2026
Same author

Fetal and neonatal alloimmune thrombocytopenia (FNAIT): Survey of UK fetal medicine centres on antenatal management of subsequent affected pregnancies.

British journal of haematology·2026
Same author

Chimeric antigen receptor T cells for autoimmune diseases, in particular immune thrombocytopenia.

British journal of haematology·2026
Same author

ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.

Blood advances·2026
Same author

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

American journal of hematology·2026

Related Experiment Video

Updated: May 1, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.4K

Primary thrombocytosis in children.

Nicole Kucine1, Katherine M Chastain, Michelle B Mahler

  • 1nik9015@med.cornell.edu.

Haematologica
|April 2, 2014
PubMed
Summary

Pediatric myeloproliferative neoplasms lack clear genetic drivers and standardized management. This review explores childhood thrombocytosis, risk stratification, and future research directions for these rare disorders.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Molecular Pathology

Background:

  • Myeloproliferative neoplasms (MPNs) are rare in children, with poorly understood pathogenesis.
  • Unlike adults, common MPN drivers like JAK2 and MPL mutations are not clearly implicated in pediatric cases.
  • Existing management strategies for adult MPNs lack direct applicability to children.

Purpose of the Study:

  • To review the current understanding of thrombocytosis in children.
  • To explore potential risk stratification and management approaches for pediatric MPNs.
  • To identify key areas for future laboratory and clinical research in pediatric MPNs.

Main Methods:

  • Literature review focusing on pediatric myeloproliferative neoplasms and thrombocytosis.
  • Analysis of existing data on adult MPN management for potential pediatric application.

More Related Videos

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

1.8K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K

Related Experiment Videos

Last Updated: May 1, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.4K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

1.8K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K
  • Discussion of current knowledge gaps and proposed research avenues.

    • Main Results:

    • Limited understanding of pediatric MPN pathogenesis, particularly regarding genetic mutations.
    • Absence of standardized diagnostic workup and management protocols for pediatric thrombocytosis.
    • Adult risk stratification and treatment guidelines are not directly transferable to pediatric populations.

    Conclusions:

    • Childhood myeloproliferative neoplasms require further investigation into their unique drivers and biology.
    • Development of pediatric-specific risk stratification and management guidelines is crucial.
    • Collaborative research efforts are needed to advance the care of children with MPNs.